文献速递炎症性肠病消化道肿瘤与早癌

老年免疫介导疾病患者使用JAK抑制剂、乌司奴单抗及抗IL-23药物的安全性

Safety of Janus kinase inhibitors, ustekinumab, and anti-interleukin-23 in older patients with immune-mediated diseases.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-10-31

JAK抑制剂与其他先进治疗相比感染风险更高(OR 1.38),但未增加MACE、VTE或恶性肿瘤风险;抗IL-12/23及抗IL-23药物较抗TNF药物严重感染风险更低(OR 0.76)。60岁以上风湿病队列中JAK抑制剂VTE风险升高,而IBD队列无此信号。

要点

  • JAK抑制剂在老年IMID患者中感染风险升高,需权衡利弊。
  • 抗IL-12/23及抗IL-23药物较抗TNF药物严重感染风险更低。
  • JAK抑制剂的VTE风险可能具有疾病特异性,风湿病中升高而IBD中无。

核心结论

  • 在老年IMID患者中,抗IL-12/23及抗IL-23药物严重感染风险较低,而JAK抑制剂感染风险升高。
  • JAK抑制剂在风湿病队列中显示可能的血栓栓塞信号,但在IBD队列中未观察到。

研究设计与样本

  • 纳入在年龄≥50岁时开始治疗的患者,比较同一治疗下年轻患者、非先进治疗或其他先进治疗。

主要发现

  • JAK抑制剂与其他先进治疗相比,感染风险OR 1.38(95% CI 1.22-1.55),严重感染OR 1.27(95% CI 1.06-1.52)。
  • 总体未观察到MACE、VTE或恶性肿瘤风险增加。
  • 60岁以上风湿病队列中VTE风险OR 3.28(95% CI 1.16-9.27),IBD队列OR 0.99(95% CI 0.58-1.70),差异P=0.045。
  • 抗IL-12/23及抗IL-23药物与抗TNF药物相比,严重感染风险OR 0.76(95% CI 0.68-0.84)。

临床怎么用

  • 老年IMID患者选择先进治疗时,需考虑感染风险,JAK抑制剂应谨慎使用。
  • 对于有血栓栓塞风险的风湿病老年患者,使用JAK抑制剂需评估VTE风险。
  • 抗IL-12/23及抗IL-23药物可作为老年患者严重感染风险较低的选项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Data on the safety of newer advanced therapies (AT) for immune-mediated inflammatory diseases (IMIDs) remain limited in older patients, and how the underlying IMID type influences treatment safety is unknown. METHODS: We systematically searched PubMed/MEDLINE and Embase for studies evaluating the safety of anti-IL12/23 and -IL23 agents, and JAKi in older patients with IMIDs, including inflammatory bowel disease, rheumatoid arthritis, and psoriasis. Eligible studies included patients who initiated therapy at age ≥50 years and reported outcomes in comparison with (1) younger patients receiving the same therapy, (2) older patients receiving non-AT, or (3) older patients receiving a different AT. Data on infections, major adverse cardiovascular events (MACE), venous thromboembolism (VTE), malignancy, and mortality were extracted. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using a DerSimonian-Laird random-effects model. RESULTS: Seventy-nine studies were included. Compared to other AT, JAKi were associated with a higher risk of infections (OR 1.38; 95% CI, 1.22-1.55) and serious infections (1.27; 1.06-1.52). No increase in MACE, VTE, or malignancy risk was seen overall. Among adults > 60 years, there was an increased risk of VTE in rheumatologic cohorts (3.28; 1.16-9.27) that was absent in IBD (0.99; 0.58-1.70) (p for difference = 0.045). Compared with anti-TNF, Anti-IL-12/23 and -IL-23 agents had a lower risk of serious infections (0.76; 0.68-0.84). CONCLUSION: In older patients with IMIDs, anti-IL-12/23 and -IL-23 agents had lower serious infection risk while JAKi had an increased risk. JAKi showed a possible disease-specific thromboembolic signal in rheumatologic but not IBD cohorts.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Le Cosquer G, Ranjan MK, Kochar B, et al. Safety of Janus kinase inhibitors, ustekinumab, and anti-interleukin-23 in older patients with immune-mediated diseases. Clin Gastroenterol Hepatol. 2026. PMID: 42966459. doi:10.1016/j.cgh.2026.10.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。